Acute toxicity of temozolomide for the treatment of anaplastic astrocytoma: A case report
| Autor: | Ashita Hulwah, Norman Djamaluddin, Yunni Diansari |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy Temozolomide business.industry Standard treatment medicine.medical_treatment Brain tumor Neoplasms. Tumors. Oncology. Including cancer and carcinogens malignant glioma temozolomide acute toxicity medicine.disease Malignancy Glioma Internal medicine medicine case report Adverse effect business RC254-282 medicine.drug Anaplastic astrocytoma |
| Zdroj: | Glioma, Vol 4, Iss 1, Pp 15-18 (2021) |
| ISSN: | 2589-6121 2589-6113 |
| Popis: | Temozolomide is an orally administered chemotherapeutic drug that has become a standard treatment for malignant gliomas. Severe toxicity of temozolomide is rare, especially shortly after administration. We report a 37-year-old male patient diagnosed with anaplastic astrocytoma following tumor resection. He was treated postoperatively with cranial radiation and adjuvant temozolomide 150 mg/m2 for six planned cycles. However, 3 days after finishing the first cycle of temozolomide, the patient's condition deteriorated. Laboratory results showed thrombocytopenia and lymphopenia, and chest X-ray revealed an infiltrate in the right segment of the lung, suggesting pneumonia. These conditions were thought to be caused by temozolomide. Although temozolomide is generally well tolerated by glioma patients, several adverse effects have been reported. In addition, malignancy, corticosteroids, and chemotherapy are known to increase the risk of immunosuppression. Close monitoring of patients treated with temozolomide is warranted, especially brain tumor patients, due to the risk of myelosuppression and severe infection. The work was approved by the Health Research Ethics Committee of DR Mohammad Hoesin Hospital (No. 130/kepkrsmh/2020) on December 15, 2020. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|